HOUSTON, Feb. 13, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials encompassing 150+ patents issued and pending, presented preclinical data that employs human dermal fibroblast (HDF) spheroids to treat an induced mouse model of psoriasis at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases during a poster presentation. See the poster "Exploring a Novel Cell-based Therapy Using Human Dermal Fibroblasts in a Mouse Model of Psoriasis" here or on the publications section of the FibroBiologics website.
"As part of our IND-enabling experiments for our early discovery phase psoriasis project, our in vivo animal studies have provided evidence that HDF spheroids have both external effects on measures of psoriasis severity in addition to a direct positive impact on reducing autoimmune inflammation," said Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics. "Cognizant of the high degree of psychological and physiological impact of psoriasis on patients, these findings indicate a potentially promising new direction for developing cell therapy-based alternative psoriasis treatments using fibroblast spheroids."
Psoriasis is an autoimmune inflammatory disorder often characterized by the development of plaques and scales on the skin, which in many individuals may lead to psoriatic arthritis. Psoriasis affects more than eight million adults in the United States alone, and FibroBiologics is investigating the therapeutic potential of HDFs for treating this disorder and providing relief to patients.
In our study using an imiquimod (IMQ)-induced psoriasis model in C57BL/6J mice, we found that a single intravenous administration of HDF spheroids significantly reduced the severity of psoriatic skin lesions, with a 35% decrease in average Psoriasis Area and Severity Index (PASI) score (p<0.0001). Systemic effects were also evident, as HDF spheroid administration ameliorated IMQ-induced changes in spleen size and lymphocyte and monocyte counts.
The ability of HDF spheroids to affect markers of psoriatic inflammation was further explored by co-culturing with human blood-derived monocytes. HDFs inhibited tumor necrosis factor (TNF)-a and interleukin (IL)-17 production in addition to suppressing cytokine-induced dendritic cell maturation by down-regulating CD40, CD80, CD86, and IL-12 and up-regulating inhibitory molecules, including IL-10, IL-1 receptor antagonist (IL-1Ra), and programmed cell death-1 (PD-L1).
For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].
Cautionary Statement Regarding Forward-Looking Statements
This communication may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning FibroBiologics' possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment, potential growth opportunities and the effects of regulation, including whether FibroBiologics will generate returns for stockholders. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth in the Risk Factors section of FibroBiologics' Registration Statement for the Direct Offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) the occurrence of any event, change or other circumstances that could cause the Registration Statement to not become effective; (b) the ability of FibroBiologics to continue to meet Nasdaq listing requirements; (c) the ability to effectively manage the business as a result of the super-voting proxy given to the Board of Directors. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics:
Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
212-845-4242
[email protected]
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]
General Inquiries:
[email protected]
SOURCE FibroBiologics
